Welcome to the e-CCO Library!

P626: Higher discontinuation rates of anti-TNF therapy in elderly IBD patients compared with a younger age group: results from a prospective registry
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Smits*1, M. de Jong1, N. den Broeder1, M. Russel2, T. Römkens3, R. West4, J. Jansen5, F. Hoentjen1

Created: Friday, 22 February 2019, 9:41 AM
P626: Safety of recombinant zoster vaccine in patients with Inflammatory Bowel Disease: a single centre experience
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Todeschini, A.(1)*;Geccherle, A.(1);Signoretto, P.(1);Variola, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P626: SARS-CoV-2 seroprevalence in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: García Mateo, S.(1,2);Martínez-Domínguez, S.J.(1,2);Aso Gonzalvo, M.C.(1);Gargallo-Puyuelo, C.J.(1,2,3);Gallego Llera, B.(1,2);Arroyo Villarino, M.T.(1,2,3);Laredo de la Torre, V.(1,2);Nocito Colon, M.M.L.(4);Lario Quilez, L.(1);Refaie, E.(5);Latre Santos, M.(3);Gomollón García, F.(1,2,3,6);
Created: Wednesday, 2 June 2021, 4:12 PM
P626: Ustekinumab for the treatment of perianal fistulas in patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Battat R.*1,2, Bessissow T.1, Strohl M.1, Kopylov U.3, Bitton A.1, Cohen A.2, Seidman E.1, Afif W.1

Created: Wednesday, 20 February 2019, 10:36 AM
P627 Acute severe ulcerative colitis in pregnancy: A retrospective cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Ollech1, I. Avni-Biron2, S. Dalal1, L. Glick1, S. Schafer1, J. Pekow1, R. Cohen1, D. Rubin1, A. Sakuraba1

Created: Thursday, 30 January 2020, 10:12 AM
P627: Change in urgency among ulcerative colitis patients: Analyses from the SPARC IBD
Year: 2021
Source: ECCO'21 Virtual
Authors: Lewis, J.(1);Shan, M.(2);Xhou, X.(2);Naegeli, A.(2);Hunter, T.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P627: HLA DQA1*05 was not associated to primary non-response or loss of response to first anti-TNF in real world Inflammatory Bowel Disease patients.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Pascual Oliver, A.(1)*;Cuarán, C.(1);Casas-Deza, D.(1,2);García-López, S.(1,2);Corsino-Roche, P.(1,2);Sierra Moros, E.(1);Julián-Gomara, A.B.(1);Vicente-Lidón, R.(1);
Created: Friday, 14 July 2023, 11:05 AM
P627: Stopping anti-tumour necrosis factor (TNF) therapy in patients with perianal Crohn’s disease: Results from a population-based study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Y. Mak*1, W. Tang1, F. K. L. Chan1, W. K. Leung2, M. K. K. Li3, F. H. Lo4, C. K. M. Ng5, A. S. F. Sze6, C. M. Leung7, S. W. C. Tsang8, E. H. S. Shan9, K. H. Chan10, B. C. Y. Lam11, A. J. Hui12, W. H. Chow13, J. J. Y. Sung1, S. C. Ng1

Created: Friday, 22 February 2019, 9:41 AM
P627: Surrogate markers of mucosal healing in Crohn's disease patients in clinical remission under biological/immunomodulator treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Siakavellas S., Kostas A., Kosmidis C., Gizis M., Papatheodoridis G., Bamias G.

Created: Wednesday, 20 February 2019, 10:36 AM
P627: Variables associated with evolution to moderate to severe Crohn's disease at two reference centers in Salvador, Bahia, Brazil
Year: 2022
Source: ECCO'22
Authors: Da Silva Beda Sacramento, C.(1);Pamponet Motta, M.(2);Oliveira Alves, C.(2);Araujo Mota, J.(3);Goes de Codes, L.M.(1);Freitas Ferreira, R.(4);de Almeida Silva, P.(4);do Prado Palmiro, L.(4);Miranda Barbosa, R.(4);Nery Andrade, M.(5);Damasceno Andrade, V.(5);Brandão Vasconcelos, V.(5);Wasconcellos Thiara, B.(6);Martins Netto, E.(7);Oliveira Santana, G.(7);
Created: Friday, 11 February 2022, 3:56 PM
P628 Histological remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Narula1, A.A. Alshahrani1, M. Fadida1, M. Al-Saedi1, J.K. Marshall1, D.T. Rubin2, B. Christensen3

Created: Thursday, 30 January 2020, 10:12 AM
P628: Anti-TNF therapy in refractory pouchitis and Crohn's disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis: a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Huguet M.1, Pereira B.2, Goutte M.1,3, Goutorbe F.1,4, Allimant C.1, Reymond M.1, Bommelaer G.1,3, Buisson A.*1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P628: Long-term outcomes with transmural healing vs. mucosal healing in Crohn’s disease: time for new treatment goals ?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. Castiglione1, N. Imperatore*1, A. Testa1, G. D. De Palma2, O. M. Nardone1, L. Pellegrini1, N. Caporaso1, A. Rispo1

Created: Friday, 22 February 2019, 9:41 AM
P628: Processed and ultra-processed food and risk of Inflammatory Bowel Disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD)
Year: 2022
Source: ECCO'22
Authors: Dong, C.(1,2);Casagrande, C.(3);Chan, S.(4,5);Huybrechts, I.(3);Nicolas, G.(3);Boutron-Ruault, M.C.(2);Carbonnel, F.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P628: Risk Factors Associated with Extraintestinal Manifestations in Patients with Inflammatory Bowel Diseases
Year: 2021
Source: ECCO'21 Virtual
Authors: Liava, C.(1);Sinakos, E.(1);Dimitroulas, T.(1);Navrozidou, C.(2);Akriviadis, E.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P628: Tofacitinib in pediatric ulcerative colitis: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ledder, O.(1)*;Dubinsky, M.(2);Dolinger, M.(2);Fatima, A.(3);Suskind, D.(4);Scarlett, J.(4);Röeser, D.(5);Shouval, D.(6);Meyer, G.(7);Molle Rios, Z.(7);Pujol, G.(8);Lozano, A.(8);Kolho, K.L.(9);Rohani, P.(10);Hussey, S.(11);de Mejj, T.(12);Ayers, T.(13);Navas López, V.M.(14);Turner, D.(1);Tzivinikos, C.(15);
Created: Friday, 14 July 2023, 11:05 AM
P628: Transfer of care of adolescent IBD patients without longitudinal transition: Lesson from 10-year experiences
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Szántó1*, K. Farkas1, M. Rutka1, A. Bálint1, R. Bor1, Á. Milassin1, A. Fábián1, Z. Szepes1, F. Nagy1, N. Vass2, D. Szűcs2, T. Molnár1

Created: Thursday, 21 February 2019, 9:14 AM
P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn’s disease (CD) in real life: Interim analysis of the SUSTAIN study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Chaparro1, S. Sulleiro2, I. Bastón-Rey3, C. Rodríguez4, I. García-Tercero5, P. Ramírez6, S. García-López7, M. Rojas-Feria8, A. Gutiérrez9, J.M. Huguet Malavés10, M.F. García-Sepulcre11, B. Sicilia12, F. Bermejo13, F. Rodríguez-Moranta14, F. Argüelles15, I. Marín16, E. Leo17, M. Arroyo18, M.J. García19, J.M. Vázquez20, D. Ginard21, J. Martínez Cadilla22, C. Rubín de Célix1, A. García-Herola23, A. Hernández-Camba24, M.D. Martín-Arranz25, S. Riestra26, P. Varela27, B. Velayos28, D. Busquets29, C. Dueñas30, E. Fernández-Salgado31, P. Martínez-Montiel32, M.T. Diz-Lois33, Y. González-Lama34, A. Muñagorri35, M. Navarro-Llavat36, C. Guisado2, M. Barreiro-de Acosta3, J.P. Gisbert1, on behalf of SUSTAIN Study Group

Created: Thursday, 30 January 2020, 10:12 AM
P629: Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one year
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Rodríguez Glez G.E.*1, Díaz Hernández L.1, Morales Barrios J.A.2, Vela González M.1, Tardillo Marín C.A.1, Viña Romero M.M.2, Rodríguez Díaz C.Y.1, Arranz Hernández L.1, Hernández Camba A.1, Merino Alonso F.J.2, Pérez Hernández F.1

Created: Wednesday, 20 February 2019, 10:36 AM